TY - JOUR
T1 - Association between the serum coenzyme q10 level and seizure control in patients with drug-resistant epilepsy
AU - Liao, Wei Chen
AU - Huang, Chin Wei
AU - Hsiao, Ya Hsin
AU - Sung, Pi Shan
AU - Fu, Tzu Fun
AU - Chang, Alice Y.W.
AU - Chang, Hui Hua
N1 - Funding Information:
Funding: This research was funded by the Ministry of Science and Technology of Taiwan (MOST 106–2320-B-006–053, MOST 107–2320-B-006–017, MOST 108–2320-B-006–047-MY3, and MOST 108– 2320-B-006–005).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/9
Y1 - 2021/9
N2 - Drug-resistant epilepsy (DRE) is a chronic neurological disorder with somatic impacts and increased risk of metabolic comorbidities. Oxidative stress might play an important role in metabolic effects and as a regulator of seizure control, while coenzyme Q10 (CoQ10) could improve insulin sensitivity through antioxidant effects. We aimed to investigate the association between CoQ10 level and clinical outcome, represented by the seizure frequency and quality of life, in DRE patients. DRE patients (N = 33) had significantly higher serum insulin levels and lower scores on the physical domain of the World Health Organization Quality of Life questionnaire (WHOQoL) than gender-age matched controls. The serum CoQ10 level (2910.4 ± 1163.7 ng/mL) was much higher in DRE patients than the normal range. Moreover, the serum CoQ10 level was significantly correlated with the seizure frequency (r = −0.412, p = 0.037) and insulin level (r = 0.409, p = 0.038). Based on stratification by insulin resistance (HOMA-IR > 2.4), the subgroup analysis showed that patients with a greater HOMA-IR had higher CoQ10 levels and lower seizure frequency, and had a significantly worse quality of life. In summary, CoQ10 could be a mediator involved in the mechanism of epilepsy and serve as a biomarker of the clinical outcome in DER patients.
AB - Drug-resistant epilepsy (DRE) is a chronic neurological disorder with somatic impacts and increased risk of metabolic comorbidities. Oxidative stress might play an important role in metabolic effects and as a regulator of seizure control, while coenzyme Q10 (CoQ10) could improve insulin sensitivity through antioxidant effects. We aimed to investigate the association between CoQ10 level and clinical outcome, represented by the seizure frequency and quality of life, in DRE patients. DRE patients (N = 33) had significantly higher serum insulin levels and lower scores on the physical domain of the World Health Organization Quality of Life questionnaire (WHOQoL) than gender-age matched controls. The serum CoQ10 level (2910.4 ± 1163.7 ng/mL) was much higher in DRE patients than the normal range. Moreover, the serum CoQ10 level was significantly correlated with the seizure frequency (r = −0.412, p = 0.037) and insulin level (r = 0.409, p = 0.038). Based on stratification by insulin resistance (HOMA-IR > 2.4), the subgroup analysis showed that patients with a greater HOMA-IR had higher CoQ10 levels and lower seizure frequency, and had a significantly worse quality of life. In summary, CoQ10 could be a mediator involved in the mechanism of epilepsy and serve as a biomarker of the clinical outcome in DER patients.
UR - http://www.scopus.com/inward/record.url?scp=85114254611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114254611&partnerID=8YFLogxK
U2 - 10.3390/healthcare9091118
DO - 10.3390/healthcare9091118
M3 - Article
AN - SCOPUS:85114254611
SN - 2227-9032
VL - 9
JO - Healthcare (Switzerland)
JF - Healthcare (Switzerland)
IS - 9
M1 - 1118
ER -